Robert Christopher Andrade Purchases 15,816 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Robert Christopher Andrade bought 15,816 shares of the stock in a transaction dated Monday, November 18th. The stock was purchased at an average price of C$3.43 per share, with a total value of C$54,248.88.

Fennec Pharmaceuticals Stock Performance

Fennec Pharmaceuticals stock opened at C$7.35 on Friday. The stock’s 50 day moving average is C$6.39 and its 200 day moving average is C$7.98. The company has a market capitalization of C$201.10 million, a P/E ratio of 65.90 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$15.43. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68.

Wall Street Analysts Forecast Growth

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.